Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: ESG

Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report


DURHAM, N.C. and BEIJING, May 6, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that it has published its first progress report on Environmental, Social and Governance (ESG) commitments as part of the Company's 2021 Annual Report.

Available on the Company's website, the progress report details Brii Bio's strategic ESG initiatives to develop a long-term, sustainable and environmentally friendly business, reviews achievements made during the 2021 fiscal year.

"As a multi-national biotechnology company, Brii Bio is driven by a patient-first and society need philosophy, dedicated to finding solutions for the world's largest public health challenges," said Zhi Hong, Ph.D., Chairman and CEO of Brii Bio. "I am so proud of our employees, investors and partners who live through our mission during the unprecedented challenges of COVID-19 knowing that we can't do it alone but we must play our part to lead by example. Brii Bio is committed to promoting public-private partnership, sustaining corporate growth and social responsibility as the company continues to grow."

Key highlights from the 2021 ESG report include:

About Brii Bio

Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.

SOURCE Brii Biosciences Limited


These press releases may also interest you

at 07:48
Gold's Gym SoCal ? the original home of fitness workouts ? celebrates its 35th anniversary, marking three and a half decades of unparalleled dedication to health, wellness, and community. To coincide with the milestone, Gold's Gym SoCal is unveiling...

at 07:44
Acclaro Medical announced that its UltraClear® 2910 nm fiber laser was awarded the "Best Laser Treatment for All Skin Tones - 2024" from NewBeauty Magazine. The win in this highly regarded and very popular publication is a repeat favorite for the...

at 06:45
The "Global Pediatric Interventional Cardiology Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to  ResearchAndMarkets.com's offering. The Global Pediatric...

at 06:30
The "Sample Preparation Market by Product (Workstation, Instrument {Pipette, Washer, Centrifuge, Grinder}, Consumable {Kits, Filters, Plates}) Technique (Solid Phase Extraction, Purification) Application (Drug Discovery, Diagnostic) - Global Forecast...

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 06:08
ConTemporary Locums, a physician-focused medical staffing company, is ushering in a new era with a bold rebrand: Era Locums. This brand evolution marks a commitment to continued innovation and a deeper connection with the company's physician and...



News published on and distributed by: